

Special Issue

Personalized Treatment for Musculoskeletal Diseases

Message from the Guest Editor

In recent years, the integration of advanced technologies and interdisciplinary research has revolutionized our comprehension of musculoskeletal diseases and treatment. These breakthroughs have empowered us to offer precise, personalized healthcare strategies for individuals grappling with musculoskeletal conditions. This Special Issue of *Journal of Personalized Medicine* serves as a beacon to illuminate the current state of scientific knowledge and spotlight the latest advancements in the realm of musculoskeletal healthcare. Our collection of studies spans a spectrum of topics, ranging from fundamental research elucidating gene-musculoskeletal interactions to clinical and population-based investigations. Through these scientific strides, we anticipate that the field of musculoskeletal medicine will continue its journey toward tailored, patient-centric care that optimizes health and well-being. This Special Issue invites experts and researchers to contribute their insights and be part of this transformative journey in musculoskeletal healthcare.

Guest Editor

Dr. Andrea Bernetti

Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, 73100 Lecce, Italy

Deadline for manuscript submissions

15 January 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/186024

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).